生产企业：Heidelberg Pharma AG
HDP-104 is an ATAC (Amanitin-based antibody-drug conjugate) candidate developed by Heidelberg Pharma, targeting gastrointestinal tumors such as colorectal cancer. It has completed preclinical development; these programs are available for partnering.
HDP-104 is an ATAC (Amanitin-based antibody-drug conjugate) candidate developed by Heidelberg Pharma, targeting gastrointestinal tumors such as colorectal cancer. It has completed preclinical development; these programs are available for partnering.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
